These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18308835)

  • 1. Mass spectrometry is only one piece of the puzzle in clinical proteomics.
    McGuire JN; Overgaard J; Pociot F
    Brief Funct Genomic Proteomic; 2008 Jan; 7(1):74-83. PubMed ID: 18308835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia.
    Forshed J; Pernemalm M; Tan CS; Lindberg M; Kanter L; Pawitan Y; Lewensohn R; Stenke L; Lehtiö J
    J Proteome Res; 2008 Jun; 7(6):2332-41. PubMed ID: 18452325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical proteomics in breast cancer: a review.
    Gast MC; Schellens JH; Beijnen JH
    Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
    Ekegren T; Hanrieder J; Bergquist J
    J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker discovery from body fluids using mass spectrometry.
    Villar-Garea A; Griese M; Imhof A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 849(1-2):105-14. PubMed ID: 17097359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synergy of elemental and biomolecular mass spectrometry: new analytical strategies in life sciences.
    Becker JS; Jakubowski N
    Chem Soc Rev; 2009 Jul; 38(7):1969-83. PubMed ID: 19551177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices.
    Poon TC
    Expert Rev Proteomics; 2007 Feb; 4(1):51-65. PubMed ID: 17288515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery.
    deVera IE; Katz JE; Agus DB
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):541-9. PubMed ID: 17147241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel approach using MALDI-TOF/TOF mass spectrometry and prestructured sample supports (AnchorChip Technology) for proteomic profiling and protein identification.
    Leung SM; Pitts RL
    Methods Mol Biol; 2008; 441():57-70. PubMed ID: 18370311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of SELDI-TOF mass spectrometry to mammalian cell culture.
    Woolley JF; Al-Rubeai M
    Biotechnol Adv; 2009; 27(2):177-84. PubMed ID: 19049820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein mass spectra data analysis for clinical biomarker discovery: a global review.
    Roy P; Truntzer C; Maucort-Boulch D; Jouve T; Molinari N
    Brief Bioinform; 2011 Mar; 12(2):176-86. PubMed ID: 20534688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics methods and applications for the practicing clinician.
    Reisdorph NA; Reisdorph R; Bowler R; Broccardo C
    Ann Allergy Asthma Immunol; 2009 Jun; 102(6):523-9. PubMed ID: 19558013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to distinguish healthy from diseased? Classification strategy for mass spectrometry-based clinical proteomics.
    Hendriks MM; Smit S; Akkermans WL; Reijmers TH; Eilers PH; Hoefsloot HC; Rubingh CM; de Koster CG; Aerts JM; Smilde AK
    Proteomics; 2007 Oct; 7(20):3672-80. PubMed ID: 17880000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives for imaging mass spectrometry in the proteomics landscape.
    MacAleese L; Stauber J; Heeren RM
    Proteomics; 2009 Feb; 9(4):819-34. PubMed ID: 19212956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry.
    Ahmed FE
    J Sep Sci; 2009 Mar; 32(5-6):771-98. PubMed ID: 19219839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Industrialized MS-based proteomics in the search for circulating biomarkers.
    Migneault I; Hunter JM
    Bioanalysis; 2009 Sep; 1(6):1149-63. PubMed ID: 21083081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic methods for biomarker discovery in urine.
    Wilkey DW; Merchant ML
    Semin Nephrol; 2007 Nov; 27(6):584-96. PubMed ID: 18061841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to dimensionality reduction in proteomic biomarker studies.
    Hilario M; Kalousis A
    Brief Bioinform; 2008 Mar; 9(2):102-18. PubMed ID: 18310106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data analysis of assorted serum peptidome profiles.
    Villanueva J; Philip J; DeNoyer L; Tempst P
    Nat Protoc; 2007; 2(3):588-602. PubMed ID: 17406620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.